

**THE PRIMARY IMMUNODEFICIENCY ASSOCIATION
(A COMPANY LIMITED BY GUARANTEE)**

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2008

Registered Charity No. 1107233

Company Registration No. 05230438

TUESDAY



AIXOVEG2

A33

27/10/2009

167

COMPANIES HOUSE

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

A. Moore
J. Drabwell
R. McNairney
D. Webster
K. Hennessy
J. Rixon

Company Secretary

C. Hughan

Chairman

D. Webster

Chief Executive

C. Hughan

Charity no

1107233

Company no

05230438

Registered office and Principal address

Alliance House
12 Caxton Street
London
SW1H 0QS

Auditors

Pinkney Keith Gibbs
35 Belmont Road
Uxbridge
Middlesex UB8 1RH

Bankers

The Royal Bank of Scotland
3rd Floor, Cavell House
2a Charing Cross Road
London WC2H 0NN

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

CONTENTS

	Page
Trustees' report	1 - 11
Auditors' report	12 - 13
Statement of financial activities	14
Balance sheet	15
Notes to the accounts	16 - 25

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008

Report of the Trustees

The Trustees have pleasure in presenting their Report and Statement of Financial Activities for the year ended 31 December 2008.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's Memorandum and Articles of Association, applicable law and the requirements of the Statement of Recommended Practice, "Accounting and Reporting by Charities" issued in 2005.

Structure, Governance and Management

Constitution

The Primary Immunodeficiency Association ("PiA") was established originally under a Trust Deed dated 14 March 1990 and registered as a charitable Unincorporated Association with the Charity Commission (number 803217). In accordance with a resolution, passed unanimously at the PiA AGM on 20 May 2006, PiA changed its constitution and legal status from an Unincorporated Association to a charitable Company limited by Guarantee (Registered in England and Wales under company number 5230438). PiA remains a Registered Charity (number 1107233) and all the activities, contracts, assets and liabilities of the previous Association have been transferred to the new Charity. It is governed by a Memorandum & Articles of Association, adopted on 4 December 2004 and approved by the Charity Commission.

Trustees, Staff and Professional Advisers

The Trustees, who are also the directors for the purpose of company law, who served during the year, were:

Dr. David Webster, MD, FRCP, FRCPath - Chairman
Mr. Andrew Moore, FCA, MA (Oxon) - Treasurer
Mrs. Jose Drabwell
Mrs. Kathryn Hennessy
Mrs. Rae McNairney
Mr. John Rixon

The Chief Executive Officer of the PiA is Christopher Hugan. In 2008 there were a further six employees (two full-time and four part-time).

The Auditors of the PiA are:

Pinkney Keith Gibbs
35 Belmont Road
Uxbridge
Middlesex UB8 1RH

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008

The Principal Bankers of the PiA are:

Royal Bank of Scotland
3rd Floor, Cavell House
2a Charing Cross Road
London WC2H 0NN

Governance

None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

The nomination of a new Trustee can be proposed by any existing Trustee or by a candidate who is a member of the Charity, putting his or her name forward for consideration. The Trustees can also co-opt Trustees at any time.

Election to the Board is for an initial period of three years. At the end of this term Trustees may offer themselves for a further term of three years. Following six years in the post Trustees would normally retire from the Board. However, in exceptional circumstances, Trustees may be elected to remain on the Board on a year-by-year basis up to a maximum of nine years, at which time they must retire.

Training and induction for new Trustees is provided as necessary.

The PiA is administered by a Trustee Board of not less than three or more than nine members, including the Chairman and Honorary Officers. These unpaid Trustees serve alongside the Chief Executive and other paid staff, on a day-to-day basis. Sub-committees are established as and when necessary.

The Board meets not less than four times a year, in addition to the Annual General Meeting. A strategy-planning meeting is held each year to carry out an in-depth view of activities and to plan for several years ahead.

The PiA has a Medical Advisory Panel, membership of which is at the invitation of the Trustee Board (through the Chief Executive). The Chairman of this Panel is an ex officio member of the Board. The functions of the Medical Advisory Panel include providing guidance and advice to the PiA on medical and associated matters, patient related issues and approving the medical content of all materials published by the PiA.

The PiA is, with three other founder charities and annually invited guest charities, a participant in the national Jeans for Genes Campaign. Jeans for Genes Limited raises funds through commercial activities for its parent undertaking, Jeans for Genes Campaign, a registered Charity. PiA's Chief Executive, Christopher Hughan, is a Director and Trustee of Jeans for Genes Campaign Limited and Jeans for Genes Limited and Ray Dias (formerly PiA's Honorary Treasurer and Trustee) is an independent Trustee and Honorary Treasurer of Jeans for Genes Campaign Limited.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008

The PiA is dependent, for a substantial part of its income, on the continuance and success of the Jeans for Genes Campaign. The PiA Trustees and Chief Executive continue to look at ways to mitigate this dependence whilst, at the same time, building up the level of free reserves.

The Trustees have reviewed other risks to which the PiA is exposed and are satisfied that internal controls are in place to mitigate these, taking into account the size of the Charity and the nature of its operations.

Objectives and Activities

The objectives of the PiA, which are set out in its Memorandum & Articles of Association, are to:

- Protect and preserve the good health of persons suffering from primary immune deficiencies (PID) (and the members of their immediate families).
- Advance education of these conditions within the medical profession, among patients and their families, and the general public.
- Promote improvements in diagnosis and provision for medical treatment.
- Encourage and support appropriate research into the diagnosis and treatment of these conditions and any other issues affecting the health of patients with these primary immune deficiencies and publish the useful results where appropriate.

The Trustees consider each of the above objectives to be of equal importance, and the work carried out during the year in achieving them can be seen in the following report, "Achievements and Performance".

Applications for research grants are advertised in recognised research journals relevant to the field of immunology. All previous grant applicants are also invited to apply. Association of Medical Research Charities (AMRC) policies are rigorously followed in the review and assessment process, using an independent external peer review group. Final decisions are made by the Trustees based on available funding and on the recommendations of the Research Grants Review Panel based on the advice received. Successful applicants are then notified and their projects monitored on a regular basis. The Research Grants Review Panel was strengthened in 2008 with the addition of two internationally eminent immunologists from both the paediatric and adult PID fields.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008

Achievements and Performance

Treatment, Outreach & Advocacy

PiA continued to work as an integral member of the editing and writing panels responsible for producing two new Consensus Documents dealing with the diagnosis and treatment of primary immunodeficiencies. One of the documents, being produced in conjunction with the Royal College of Physicians, will contain definitive guidelines for the 'gold standard' management and treatment of Primary Antibody Deficiencies (PAD). The other document, a guide to primary immunodeficiencies, is targeted at Health Service Managers and Commissioners, as well as those in the primary care sector and other medical professionals not coming into contact with PID patients on a regular basis. Both of these important publications are in progress and PiA will work closely with the editorial teams to ensure these important guidelines are distributed widely to all relevant UK medical and healthcare professionals and other key audiences, such as Government.

Over the year, Chief Executive, Chris Hughan, actively represented the interests of PiA members/patients in a number of situations that threatened the continuity and quality of patient treatments and care.

Initiated in 2006 and continuing well into 2008, a comprehensive consultation process with Deloitte, the management consultancy producing the Review of Intravenous immune globulin (IVIg) Demand, Supply and Usage in England on behalf of the Department of Health, resulted in a very positive result for PID patients. When the guidelines for future IVIg use were published PID patients were the only group prioritised for IVIg treatment, even during times of product shortages.

PiA will continue to monitor the IVIg usage guidelines and demand management programmes being undertaken by the Department of Health, as well as representing and safeguarding the interests of PID patients whenever these are under threat. As a result of its involvement in the IVIg Review in England the Scottish Authorities have invited PiA to represent the interests of Scottish PID patients in a similar review of IVIg usage being conducted in Scotland in 2008/9.

PiA staff and Trustees visited several major PID clinics throughout the UK during the year.

The Chief Executive attended and played an active role in a number of key medical meetings where he represented the views and interests of PID patients, including regular meetings of the Steering Committee of UK PIN (the national professional association for Immunologists and Specialist Immunology Nurses), the Pan London PID Consortium (Clinical Immunologists and Specialist Immunology Nurses from centres across London), the UK PIN Sub-Committee overseeing the operation and development of the UK PID Registry, BSI-CIAS (the Clinical Immunology and Allergy Sub-Committee of the British Society for Immunology representing the clinical aspect of Immunology) and the European Society of Immunodeficiencies Biannual Meeting in Holland.

In addition to representing the interests of PID patients on all these important committees and professional groups, PiA also dealt with an increasing number of individual problems with treatment sourcing and funding encountered by PID patients.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008

Patient Support

A number of regional events were organised and held in 2008, including Regional Patient Days in the West Country, Birmingham, London and Wales. Chris Hughan, the Chief Executive, attended and spoke at most of these events. These meetings continue to prove very popular with patients and their families and an expanded programme will be planned for 2009, covering additional centres. Smaller, more informal meetings of medical professionals, PiA and patients are also being considered in areas where there are fewer PID patients or a larger meeting is not warranted.

For young PID patients PiA organised two successful three-day Canal Boat holidays in late Summer and earlier in the year a group of young adults travelled to Center Parcs in Sherwood Forest for a week-long activity holiday – both events being closely supervised by trained PiA volunteers and local experts.

PiA staff attended meetings of IVIg manufacturers in the UK to put the patient perspective to staff and senior executives. As a result of these visits and other activities PiA is increasingly involved in the consultation process leading to new product launches and marketing of IVIg, subcutaneous and Hereditary Angioedema (HAE) treatments and even in the production of relevant literature by the various pharmaceutical companies.

PiA's Welfare & Benefits Adviser, Jenny Jackson, continued to provide an invaluable service to PiA members, assisting 21 members seeking Disability Living Allowance (DLA) and Attendance Allowance (AA) in the year in addition to 20 other cases where decisions were awaited. Awards of £60,000 were made in 2008, of which £52,000 was to new recipients. A new guide to help members claim DLA proved very popular with members and in addition to being sent by post on request, this guide has now been uploaded onto the PiA website for easy downloading by members who use the Internet.

Five membership mailings were sent out to members/patients and their families during the year, some of which included copies of PiA's popular newsletter, InSight. More publications are planned for 2009, including a new member information pack and useful tips for young PID patients attending University.

The PiA website continued to be popular with members and other visitors and received a record number of 'hits' during the year. The website, which is due for redesign and upgrading in 2009, is currently monitored, supervised and updated by PiA staff member, John Satchell.

Medical and Research

A number of research initiatives were undertaken by PiA during the year in addition to the ongoing research commitment.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008

PiA was invited by leading pharmaceutical company, GlaxoSmithKline (GSK), to submit a research proposal for one of its prestigious Medical Research Awards. Following an open invitation by PiA to all interested research centres in the UK three applications were eventually received and peer reviewed. The selected application was submitted to GSK for assessment by its own team of medical experts. Against competition from several leading charities, some much larger than PiA, the Charity was successful in obtaining a grant for £165,000 over three years for an international research study on familial links in Common variable immunodeficiency disorders (CVID), being conducted by Professor Bodo Grimbacher and his team at the Royal Free Hospital in London. This research commenced in 2008.

Concerned about the continuing lack of progress in defining accurately the numbers of patients in the UK with various primary immunodeficiency disorders and gathering important statistics and information relating to their diagnosis, management and treatment, PiA took the initiative and supported the establishment and ongoing development of a new UK Registry of PID Patients. The Registry, which has the full backing of UK PIN and the Royal College of Nursing Immunology and Allergy Specialist Nurses Group, gathers this information from each PID centre, and the information provided is then updated annually. It will be housed on PiA-funded UK-based secure servers at University College London. PiA has provided funding of £107,445 over three years to support a highly trained, data input specialist who will visit all the leading PID centres to help input data, once the normal ethical and patient clearances have been obtained. The Charity has also funded the servers and associated equipment on which the Registry is stored. At the end of 2008 over 700 UK PID patients and their details had been entered anonymously on the Registry.

To encourage more medical students to consider a career in Immunology, and PID in particular, PiA created and funded up to three bursary awards annually for medical students taking the Bachelor of Medical Science (BMedSci) Intercalated Degree. To qualify for the bursary – intended to cover their costs during the year of study – students have to undertake a qualifying research project in a PID related study, working under the guidance of an appropriate supervisor. A pilot of the scheme was initiated at UCL in 2008. It is hoped to expand the bursary scheme in future years to other centres where Intercalated Degrees in an Immunology (PID) related subject are offered.

In addition to these new initiatives PiA continued to fund major research projects being conducted by Dr. Stephen Jolles and his colleagues in Cardiff (£99,775 over three years) and Dr. Siobhan Burns at London's Institute of Child Health (£270,220 over four years).

Dr. Helen Chapel and her team at Oxford's Centre for Clinical Immunology received the final tranche of a five-year (£100,000) "Centre of Excellence" award for a range of research projects into PID, including cellular and molecular studies into CVID.

As Jeans for Genes distributed income was at a record low in 2008 and because of PiA's existing research commitments and new initiatives, the Trustees felt it would not be fiscally prudent to offer additional substantial research grants in the year ahead. However, every effort will be made in 2009 to obtain research funding from other (than J4G) sources, such as that provided by GSK.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008

The Chair of the PiA's Medical Advisory Panel (MAP) is Dr Aarnoud Huissoon. He is a Consultant Immunologist at Birmingham Heartlands Hospital. Dr Hilary Longhurst, Consultant Immunologist at Barts and The London NHS Trust, is the Vice-Chair. The Board includes three specialist immunology nurses, Sister Fran Ashworth of Sheffield's Northern General Hospital, Sister Janet Burton of Oxford's John Radcliffe Hospital and Sister Lucia Russell of Newcastle General Hospital. There are likely to be further additions to the MAP in 2009, as well as the establishment of a Specialist Immunology Nurses Advisory Panel for the first time. A review of PiA's Research Grants Review Panel was begun in 2007 and was completed in 2008.

Fundraising

In fundraising terms the year was a 'mixed bag'. On the positive side the Charity received the second year's tranche of its first major Lottery Grant but unfortunately this additional revenue and other gains were effectively cancelled out by much lower than anticipated Jeans for Genes distributed income.

The Lottery Grant – an award from the Big Lottery Fund under its "Reaching Communities" programme – is in its second of the three years awarded and was awarded to help PiA develop its volunteer base, local support groups, youth and other PID 'community' involvement and volunteer related activities. PiA is also into the second year of a three-year grant from BBC's "Children In Need" Campaign to help with PID children related activities such as the Canal Boat and Activity Centre holidays.

Although pharmaceutical income was down on the previous year because of highly competitive market conditions, PiA's excellent relationship with these companies still yielded significant funds and a commitment to engage in a broader spectrum of projects over the years ahead. PiA will partner the pharma companies in joint Patients Days, literature production, research studies and other projects in 2009, ensuring that any cooperation does not compromise the independent position of the Charity and its freedom to criticise the pharma companies as and when this might be necessary.

PiA members and supporters were once again very generous in their support of the Charity and donation income was much in line with previous years. Support provided through member fundraising events was considerable, and PiA hopes that more members will once again organise events to raise funds for the Charity in 2009.

There was a steady growth in members making donations to PiA through standing orders and direct debits and the Charity hopes that more members will use this convenient method to give regularly to PiA and its work over the coming years.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008

Jeans for Genes (J4G) income reached a new low in 2008, although there were a number of known factors that contributed to this reduced contribution – factors that are unlikely to be repeated in the years ahead. It has taken longer than expected for the Chief Executive of J4G, Caroline Harding, to re-organise and re-energise the fund raising initiatives. PiA is confident that the Chief Executive's considerable experience and marketing and management skills will help turn around the fortunes of the high profile J4G campaign and restore a higher level of revenue generation and thus distributed income to PiA and the other partner and guest charities in the years ahead. PiA Chief Executive, Chris Hughan, who is also a J4G Trustee, continues to work closely with the J4G team to maximise the involvement of PiA and help revitalise the J4G campaign in the medium to long term.

- The Charity was fortunate to be awarded five 'gold bond' places in the 2008 London Marathon after many years on the waiting list. Combined with other places already purchased by PiA and supporters with guaranteed places already running for PiA, the Charity had a record turnout and a consequent substantial increase in sponsorship income. PiA also had a number of sponsored runners in other Marathons and runs in 2008 and is building income in this important fundraising area.
- Although the Christmas Draw was a fundraising success the sale of Christmas cards and related merchandise was somewhat disappointing, resulting in a below budget drop in overall income. A review of the Christmas card selection and marketing was conducted for 2008 to provide a more appealing selection of cards at attractive price points. Additional sites for card sales have been negotiated for 2009.
- The Trustees and PiA staff thank PiA members and supporters for all their hard work and fundraising efforts in 2008 and look forward to their continued and much valued support in 2009.

Staff

Brenda Cherry left PiA in October 2008 to take up a post closer to her home in West Sussex. There were no other significant staff changes during the year.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008

Financial Review

Results

Total income was lower than in the previous year at £429,723 (2007 £706,590). Although a little disappointing, the result is far more satisfactory when the very significant drop in income from PiA's historic major source of revenue, Jeans for Genes is taken into consideration. Jeans for Genes revenue was £181,180 against £272,017 in 2007, a drop of £90,837. Despite the re-organisation of the fundraising initiatives following the appointment of a new J4G Chief Executive in 2006, donation income was well down – as were the number of fundraising coordinators participating in the campaign. As stated earlier in this report, the new J4G Chief Executive is making a number of major changes to the structure of the J4G campaign, as well as to the campaign team and marketing strategy and programmes. It is anticipated that this will help turn around the fortunes of the J4G 'brand' and result in increased revenue generation in 2009 and beyond.

PiA continued its successful 'challenge' fundraising events in the year and, along with revenue from running events, this generated £32,342 of gross income. The Charity also received £55,252 in Big Lottery funding during the year.

PiA generated a deficit of £2,793 on the general fund for the year (2007 surplus £104,460).

Reserves Policy

The Board has established a policy whereby the unrestricted funds not committed that are held by the PiA should be between three and nine months of total expenditure, excluding research grants. Free reserves of £201,796 at 31 December 2008 represent just over six months of operational expenditure.

Investment Policy

Under its Memorandum & Articles of Association the PiA has the power to make any investment that the Trustees feel is appropriate. In the year under review PiA no longer holds any such investments and bank deposits are classed as current assets as appropriate.

Plans for Future Periods

During 2008, as in the previous year, the priority was to enhance the Charity's free reserves situation and achieve a more financially robust position entering 2009. This objective was maintained.

In 2009 the Charity will build on its fundraising successes and will seek additional funding from existing and new sources as well as higher profile participation in events such as the London Marathon and other such runs. A decision on participation in another 'challenge' event will depend to a large extent on potential participant reaction.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008

An expanded programme of patient support activities and events were run in 2008, including an increased number of regional patient days and Canal Boat and Sherwood Forest activity holidays for younger PID patients. PiA will continue to advocate aggressively on behalf of its members, collectively and individually, and will monitor changes in Health Service provision in all regions to ensure that the rights of PID patients are preserved and protected.

The Charity will continue to offer its members a free support and advisory service, including benefits and welfare advice and information and materials to help PID patients cope with significant moments of change in their lives.

PiA will continue to work with leading medical professionals to produce guidelines on the best forms of treatment for PID patients and with the pharmaceutical companies on the development and marketing of new treatments for all PID patients, including Hereditary Angioedema.

Dependent on a significant improvement in 2009 Jeans for Genes revenues, PiA will consider another round of research funding towards the end of 2009. In the meantime the Charity will continue to invest in its substantial, ongoing programme of PID research, fund a number of strategically important new initiatives, such as the Intercalated Degree Bursary Awards and the UK PID Register, and seek significant funding for additional research from its own fundraising programme – such as the GSK award.

Although the environment in the charitable sector continues to be highly competitive and the economic conditions in the UK increasingly challenging, the Trustees believe PiA is a stronger and more effective charity at the end of 2008, better able to meet its growth aspirations and provide the required level of advisory, educational, advocacy and support services to all people with primary immunodeficiencies in the UK.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION**REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2008**

Statement of trustees' responsibilities

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the Charity and the incoming resources and application of resources, including the net income or expenditure for the year. In preparing these financial statements, the trustees are required to:


- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation.

The trustees are responsible for keeping accounting records which disclose with reasonable accuracy the financial position of the Charity and which enable them to ascertain the financial position of the Charity and which enable them to ensure that the financial statements comply with applicable law, regulations and trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement of disclosure to auditor

- (a) So far as the trustees are aware, there is no relevant audit information of which the Charity's auditors are unaware, and
- (b) They have taken all the steps that they ought to have taken as trustees in order to make themselves aware of any relevant audit information and to establish that the Charity's auditors are aware of that information.

**Approved by the Board of Trustees on
and signed on its behalf by:**


A. Moore
Director

REPORT OF THE AUDITORS TO THE TRUSTEES OF THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

Independent Auditors' Report to the Trustees of The Primary Immunodeficiency Association

We have audited the financial statements of The Primary Immunodeficiency Association for the year ended 31 December 2008, which comprise the statement of financial activities, the balance sheet, and the related notes on pages 14 to 25. These financial statements have been prepared under the accounting policies set out in pages 16 to 17.

This report is made solely to the Charity's members, as a body, in accordance with section 235 of the Companies Act 1985. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity and the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of Trustees and auditors

The trustees' (who are also the directors of The Primary Immunodeficiency Association for the purposes of company law) responsibilities for preparing the trustees' Annual Report and the Financial Statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) are set out in the statement of trustees' Responsibilities.

Our responsibility is to audit the Financial Statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the Financial Statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you whether in our opinion the information given in the trustees' Annual Report is consistent with the financial statements.

In addition we report to you if, in our opinion, the Charity has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding trustees' remuneration and other transactions is not disclosed.

We read the trustees' Annual Report and consider the implications for our report if we become aware of any apparent misstatements within it.

Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the trustees in the preparation of the financial statements, and of whether the accounting policies are appropriate to the Charity's circumstances, consistently applied and adequately disclosed.

**REPORT OF THE AUDITORS TO THE TRUSTEES OF
THE PRIMARY IMMUNODEFICIENCY ASSOCIATION**

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion:

- the Financial Statements give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice applicable to Smaller Entities of the state of the Charity's affairs as at 31 December 2008 and of its incoming resources and application of resources, including its income and expenditure, in the year then ended;
- the Financial Statements have been properly prepared in accordance with the Companies Act 1985; and
- the information given in the trustees' Annual Report is consistent with the financial statements.

Pinkney Keith Gibbs

35 Belmont Road
Uxbridge
Middlesex UB8 1RH

PINKNEY KEITH GIBBS
Chartered Accountants
Registered Auditors

25 Oct 2009

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2008

	Note					(as restated)			
		General Funds	Unrestricted Research	Restricted Research	Total 2008	General Funds	Unrestricted Research	Restricted Research	Total 2007
		£	£	£	£	£	£	£	£
INCOMING RESOURCES									
Incoming resources from generated funds									
Voluntary income	6	308,171	-	55,252	363,423	357,880	42,000	210,360	610,240
Pharmaceutical Company donations	7	31,089	-	-	31,089	63,363	-	-	63,363
Investment income	8	22,003	-	-	22,003	20,844	-	-	20,844
		<u>361,263</u>	<u>-</u>	<u>55,252</u>	<u>416,515</u>	<u>442,087</u>	<u>42,000</u>	<u>210,360</u>	<u>694,447</u>
Other incoming resources		13,208	-	-	13,208	12,143	-	-	12,143
TOTAL INCOMING RESOURCES		<u>374,471</u>	<u>-</u>	<u>55,252</u>	<u>429,723</u>	<u>454,230</u>	<u>42,000</u>	<u>210,360</u>	<u>706,590</u>
RESOURCES EXPENDED									
Costs of generated funds									
Fundraising		16,088	-	8,662	24,750	24,002	-	10,287	34,289
Charitable activities	9a	328,087	115,044	122,677	565,808	302,319	168,447	52,166	522,932
Governance Costs	10	10,243	-	-	10,243	6,347	-	-	6,347
TOTAL RESOURCES EXPENDED		<u>354,418</u>	<u>115,044</u>	<u>131,339</u>	<u>600,801</u>	<u>332,668</u>	<u>168,447</u>	<u>62,453</u>	<u>563,568</u>
Net (resources expended)/ incoming resources before transfers		20,053	(115,044)	(76,087)	(171,078)	121,562	(126,447)	147,907	143,022
Transfers between funds		(22,846)	-	22,846	-	(17,102)	9	17,093	-
NET MOVEMENT IN FUNDS		<u>(2,793)</u>	<u>(115,044)</u>	<u>(53,241)</u>	<u>(171,078)</u>	<u>104,460</u>	<u>(126,438)</u>	<u>165,000</u>	<u>143,022</u>
FUNDS BROUGHT FORWARD AT 1 JANUARY 2008	14	<u>204,589</u>	<u>302,841</u>	<u>175,269</u>	<u>682,699</u>	<u>100,129</u>	<u>429,279</u>	<u>10,269</u>	<u>539,677</u>
FUNDS CARRIED FORWARD AT 31 DECEMBER 2008	14	<u>201,796</u>	<u>187,797</u>	<u>122,028</u>	<u>511,621</u>	<u>204,589</u>	<u>302,841</u>	<u>175,269</u>	<u>682,699</u>

The Statement of Financial Activities also complies with the requirements for an income and expenditure account under the Companies Act 1985.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

BALANCE SHEET AT 31 DECEMBER 2008

	Note	£	£	2007 £
FIXED ASSETS				
Tangible assets	11		16,749	1,734
CURRENT ASSETS				
Stock		2,339		1,815
Debtors	12	261,795		113,391
Cash at bank and in hand		15,462		270,112
Funds on deposit		333,381		438,701
			612,977	824,019
			629,726	825,753
CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	13		(118,105)	(143,054)
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>511,621</u>	<u>682,699</u>
FUNDS				
General fund	14		201,796	204,589
Unrestricted Research Fund	14		187,797	302,841
Restricted Research Fund	14		122,028	175,269
			<u>511,621</u>	<u>682,699</u>

The financial statements have been prepared in accordance with the special provisions of Part VII of the Companies Act 1985 relating to smaller companies and with the Financial Reporting for Smaller Entities (effective January 2007).

The accounts were formally approved by the Board on 23rd October 2009


A. Moore
Director

Company Registration No. 05230438

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2008

1. ACCOUNTING POLICIES

(a) Basis of accounting

The Accounts are prepared under the historical cost convention and in accordance with the Statement of Recommended Practice, "Accounting and Reporting by Charities" issued in 2005 (SORP 2005), the Financial Reporting Standard for Smaller Entities (effective January 2007) and the Companies Act 1985.

(b) Incoming resources

All incoming resources are included in the Statement of Financial Activities ("SOFA") when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income.

- Grants, donations, gifts and legacies are included in the SOFA as they are received. Grants, where entitlement is not conditional on the delivery of a specific performance by the Charity, are recognised when the Charity becomes unconditionally entitled to the grant.
- Cash collected at special fundraising events is included in the SOFA before deducting the expenditure incurred directly in staging the event.
- The value of voluntary help is not included in the accounts.
- Bank interest is included in the SOFA on receipt.
- Incoming resources from grants, where related to performance and specific deliverables, are accounted for as and when the Charity earns the right to consideration by its performance.

(c) Resources expended

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Fundraising costs are those costs incurred in seeking voluntary contributions.

Charitable activities comprise expenditure on the Charity's day to day administration, plus projects that the Charity and third parties have designated funds for. This includes expenditure on research grants, which are approved by the trustees on annual basis and allocated to specific funds in the next financial year.

Governance costs are those incurred in connection with the constitutional and statutory requirements of the Charity.

(d) Operating leases

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to the SOFA.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS (continued) FOR THE YEAR ENDED 31 DECEMBER 2008

(e) Pensions

The Charity operates a defined contribution scheme for the benefit of its employees. Pension contributions are charged to the SOFA in the year they are payable.

(f) Irrecoverable Value Added Tax

The Charity is not registered for Value Added Tax. All irrecoverable Value Added Tax is included within the expense heading in which the expense is incurred.

(g) Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

Office equipment	33.33% on cost
------------------	----------------

(h) Funds

The funds are determined on the basis of the entity making the donation i.e. some donors stipulate that the donation is for a certain research project and as such is part of the research fund.

Restricted research funds comprise of funds that have been specifically designated by the entity making the donation and should be used by the Charity in accordance with the terms set out by the donor.

There has been a change in presentation with regard to the grant received from the Big Lottery Fund and the subsequent expenditure from the grant. This is a restricted fund and has been previously shown incorrectly within general funds. The comparatives have been restated to reflect the change as required. As the fund was £nil at 31 December 2007 a prior year adjustment was not necessary.

Unrestricted research funds comprise of funds that were not received for a specific research project, but have since been allocated by the trustees to research.

The Jeans for Genes founder charities (including PiA) received special dispensation in 2007 and 2008 from Jeans for Genes to allocate distributed funds to research or support activity at whatever level they considered prudent and appropriate. PiA have not allocated any funds to research this year (PiA allocated £42,000 to research in 2007). In previous years the income was split on the basis of 40% support services, and 60% research (less a research overhead recovery charge). (See note 17).

General funds comprise of funds that can be spent at the discretion of the trustees for any purpose of the Charity. These funds have not been allocated to research and are used by the Charity to cover its day-to day costs.

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS (continued) FOR THE YEAR ENDED 31 DECEMBER 2008

2. TRUSTEES' REMUNERATION AND REIMBURSED EXPENDITURE

The trustees were not entitled to and received no remuneration from the Charity during the year. Trustees were reimbursed expenses from the Charity for meetings and activities that they attended, these amounts totalled £ 3,658 (2007: £1,972).

3. EMPLOYEES' REMUNERATION

The average number of employees during the year was 7 (2007: 6). The total costs of the employees including temporary staff is as follows:

	2008 £	2007 £
Salary costs	184,821	157,580
Employers NIC	18,434	16,247
Pension contributions	13,009	11,023
Recruitment/training costs	782	102
	<u>217,046</u>	<u>184,952</u>

The number of employees whose emoluments as defined for taxation purposes amounted to over £60,000 in the year was as follows:

	2008 Number	2007 Number
£60,001 - £70,000	<u>1</u>	<u>1</u>

4. PENSION COST

The Charity contributes towards employees' personal pension schemes. The contributions for the year amounted to £13,009 (2007: £11,023). £1,747 (2007: £809) was outstanding as at the year-end.

5. NET MOVEMENT IN FUNDS

	2008 £	2007 £
This is stated after charging:		
Depreciation	8,808	867
Auditors' remuneration	<u>3,450</u>	<u>3,290</u>
	<u>12,258</u>	<u>4,157</u>

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 DECEMBER 2008

6. VOLUNTARY INCOME

(as restated)

	General Fund	Unrestricted Research	Restricted Research	2008 Total	General Fund	Unrestricted Research	Restricted Research	2007 Total
	£	£	£	£	£	£	£	£
Membership subscriptions and donations	26,408	-	-	26,408	27,111	-	-	27,111
Members fundraising activities	20,127	-	-	20,127	15,003	-	-	15,003
Annual draw and Christmas card sales	19,022	-	-	19,022	16,226	-	-	16,226
Corporate and trust donations and fundraising	26,110	-	-	26,110	21,557	-	-	21,557
Legacy individuals	4,162	-	-	4,162	1,500	-	-	1,500
PiA organised events	32,342	-	-	32,342	51,648	-	-	51,648
Big Lottery Fund grant	-	-	55,252	55,252	-	-	45,360	45,360
GlaxoSmithKline	-	-	-	-	-	-	165,000	165,000
Jeans for Genes	180,000	-	-	180,000	224,835	42,000	-	266,835
	<u>308,171</u>	<u>-</u>	<u>55,252</u>	<u>363,423</u>	<u>357,880</u>	<u>42,000</u>	<u>210,360</u>	<u>610,240</u>

7. PHARMACEUTICAL COMPANY DONATIONS

	General Fund	Unrestricted Research	Restricted Research	2008 Total	General Fund	Unrestricted Research	Restricted Research	2007 Total
	£	£	£	£	£	£	£	£
Grifols UK	2,500	-	-	2,500	15,000	-	-	15,000
Baxter	-	-	-	-	10,000	-	-	10,000
Bio-Products Laboratory	7,500	-	-	7,500	15,000	-	-	15,000
CSL Behring	12,500	-	-	12,500	15,000	-	-	15,000
Octapharma	2,500	-	-	2,500	5,000	-	-	5,000
Bio-test	2,500	-	-	2,500	-	-	-	-
Jcrini	3,589	-	-	3,589	663	-	-	663
AGM	-	-	-	-	2,700	-	-	2,700
	<u>31,089</u>	<u>-</u>	<u>-</u>	<u>31,089</u>	<u>63,363</u>	<u>-</u>	<u>-</u>	<u>63,363</u>

8. INVESTMENT INCOME

	General Fund	Unrestricted Research	Restricted Research	2008 Total	General Fund	Unrestricted Research	Restricted Research	2007 Total
	£	£	£	£	£	£	£	£
Bank interest	22,003	-	-	22,003	20,844	-	-	20,844
	<u>22,003</u>	<u>-</u>	<u>-</u>	<u>22,003</u>	<u>20,844</u>	<u>-</u>	<u>-</u>	<u>20,844</u>

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS (Continued)
FOR THE YEAR ENDED 31 DECEMBER 2008

9a CHARITABLE ACTIVITIES

DIRECT CHARITABLE EXPENDITURE	General Fund £	Unrestricted Research £	Restricted Research £	2008 Total £	(as restated)			
					General Fund £	Unrestricted Research £	Restricted Research £	2007 Total £
Meeting costs	6,830	-	15,937	22,767	13,117	-	5,622	18,739
Insight expenses	9,444	-	2,361	11,805	11,757	-	5,038	16,795
Regional days costs	2,094	-	2,560	4,654	5,009	-	2,146	7,155
Other projects	7,688	-	2,562	10,250	14,501	-	3,625	18,126
Volunteer expenses	43	-	64	107	-	-	166	166
Research expenditure - note 9b	-	115,044	53,241	168,285	-	168,447	(9)	168,438
	<u>26,099</u>	<u>115,044</u>	<u>76,725</u>	<u>217,868</u>	<u>44,384</u>	<u>168,447</u>	<u>16,588</u>	<u>229,419</u>
SUPPORT COSTS								
Staff costs								
Support staff wages	80,835	-	20,681	101,516	63,215	-	12,786	76,001
Admin staff wages	96,212	-	5,527	101,739	92,511	-	5,315	97,826
Staff pensions	13,009	-	-	13,009	11,023	-	-	11,023
Staff recruitment & training	782	-	-	782	102	-	-	102
Staff welfare	1,160	-	-	1,160	967	-	-	967
	<u>191,998</u>	<u>-</u>	<u>26,208</u>	<u>218,206</u>	<u>167,818</u>	<u>-</u>	<u>18,101</u>	<u>185,919</u>
Rent and services								
Rent and rates	39,023	-	5,894	44,917	35,226	-	7,521	42,747
Office insurance	1,090	-	-	1,090	376	-	-	376
Light and heat	1,480	-	293	1,773	1,739	-	-	1,739
Telephone	504	-	3,239	3,743	590	-	4,169	4,759
Cleaning	3,398	-	-	3,398	3,023	-	-	3,023
Repairs and maintenance	-	-	-	-	50	-	-	50
	<u>45,495</u>	<u>-</u>	<u>9,426</u>	<u>54,921</u>	<u>41,004</u>	<u>-</u>	<u>11,690</u>	<u>52,694</u>
Other expenses								
Printing, post and stationery	5,878	-	2,123	8,001	5,387	-	2,053	7,440
Advertising	601	-	67	668	-	-	886	886
Computer costs	8,069	-	1,599	9,668	4,879	-	2,360	7,239
Equipment hire	6,176	-	3,326	9,502	10,126	-	-	10,126
Legal fees	2,652	-	-	2,652	10,391	-	-	10,391
Consultancy	26,264	-	3,203	29,467	9,367	-	488	9,855
Payroll service costs	625	-	-	625	588	-	-	588
Bank charges	1,283	-	-	1,283	1,304	-	-	1,304
Subscriptions	3,819	-	-	3,819	3,210	-	-	3,210
Sundry expense	320	-	-	320	6	-	-	6
Office equipment depreciation	8,808	-	-	8,808	867	-	-	867
Loss on disposal of fixed assets	-	-	-	-	2,988	-	-	2,988
	<u>64,495</u>	<u>-</u>	<u>10,318</u>	<u>74,813</u>	<u>49,113</u>	<u>-</u>	<u>5,787</u>	<u>54,900</u>
TOTAL CHARITABLE ACTIVITIES	<u>328,087</u>	<u>115,044</u>	<u>122,677</u>	<u>565,808</u>	<u>302,319</u>	<u>168,447</u>	<u>52,166</u>	<u>522,932</u>

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS (Continued)
FOR THE YEAR ENDED 31 DECEMBER 2008

9b. RESEARCH FUNDS

	Balance 31.12.07	Receipts in year	Allocations	Expenditure in year	Balance 31.12.08
	£	£	£	£	£
Unrestricted research funds					
Jeans for Genes - unallocated	39,937	-	-	-	39,937
PID Register	92,197	-	-	(35,620)	56,577
Intercalated Degrees	6,500	-	-	-	6,500
Jolles - NIMR/RFH	24,125	-	-	(3,526)	20,599
AMS Project	120,082	-	-	(55,898)	64,184
Centre of Excellence	20,000	-	-	(20,000)	-
	<u>302,841</u>	<u>-</u>	<u>-</u>	<u>(115,044)</u>	<u>187,797</u>
Restricted research funds					
BCH	10,269	-	-	-	10,269
GlaxoSmithKline	165,000	-	-	(53,241)	111,759
Big Lottery Fund	-	55,252	22,846	(78,098)	-
	<u>175,269</u>	<u>55,252</u>	<u>22,846</u>	<u>(131,339)</u>	<u>122,028</u>
	<u>478,110</u>	<u>55,252</u>	<u>22,846</u>	<u>(246,383)</u>	<u>309,825</u>
Total Funds					

Each year research grants are approved by the trustees in December and then communicated to those concerned with conditions attached for acceptance. Once the final acceptances are received the allocation is made in the next financial year.

10. GOVERNANCE COSTS

	General Fund £	Unrestricted Research £	Restricted Research £	2008 Total £	General Fund £	Unrestricted Research £	Restricted Research £	2007 Total £
Trustees insurances	996	-	-	996	1,085	-	-	1,085
Trustees expenses	3,658	-	-	3,658	1,972	-	-	1,972
Audit fee	3,450	-	-	3,450	3,290	-	-	3,290
Legal fees	2,139	-	-	2,139	-	-	-	-
	<u>10,243</u>	<u>-</u>	<u>-</u>	<u>10,243</u>	<u>6,347</u>	<u>-</u>	<u>-</u>	<u>6,347</u>

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 DECEMBER 2008

11. FIXED ASSETS

	Fixtures, Fittings and Equipment £
COST	
As at 1 January 2008	2,601
Additions during year	23,823
	<u>26,424</u>
Total as at 31 December 2008	<u>26,424</u>
DEPRECIATION	
As at 1 January 2008	867
Charged in year	8,808
	<u>9,675</u>
Total as at 31 December 2008	<u>9,675</u>
NET BOOK VALUE	
31 December 2008	<u>16,749</u>
31 December 2007	<u>1,734</u>

12. DEBTORS

	2008 £	2007 £
Other debtors	7,262	38,742
Prepayments and accrued income	<u>254,533</u>	<u>74,649</u>
	<u>261,795</u>	<u>113,391</u>

Jeans for Genes

The Jeans for Genes Day is held in October and therefore the funds raised and costs relating thereto are not known by the time the financial statements are prepared. The Treasurer has estimated that the amount still to be received will be £186,178 (2007: £6,178) (See note 17).

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

**NOTES TO THE FINANCIAL STATEMENTS (Continued)
FOR THE YEAR ENDED 31 DECEMBER 2008**

13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2008 £	2007 £
Taxation & social security	3,969	5,557
Accruals	77,832	98,604
Deferred income	11,036	14,673
Other creditors	25,268	24,220
	<u>118,105</u>	<u>143,054</u>

Incoming resources that has been deferred are as follows; £

Big Lottery Fund	9,277
2009 Flora London Marathon	<u>1,759</u>
	<u>11,036</u>

Deferred income relates to income that has been received prior to the year end that relates to performance and specific deliverables that has not been achieved at the year end. As such the Charity accounts for the income as it earns the right to consideration by its performance.

The movement in deferred income is as follows: £

At 1 January 2008	14,673
Transfer to the SOFA	(14,673)
Additional deferred income	<u>11,036</u>
At 31 December 2009	<u>11,036</u>

14. FUNDS

	General Funds £	Unrestricted Research £	Restricted Research £	Total £
At 1 January 2008	204,589	302,841	175,269	682,699
Net movement in funds	<u>(2,793)</u>	<u>(115,044)</u>	<u>(53,241)</u>	<u>(171,078)</u>
At 31 December 2008	<u>201,796</u>	<u>187,797</u>	<u>122,028</u>	<u>511,621</u>

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

NOTES TO THE FINANCIAL STATEMENTS (Continued) FOR THE YEAR ENDED 31 DECEMBER 2008

15. FINANCIAL COMMITMENTS

At 31 December 2008, the Charity had annual commitments under a non-cancellable operating lease as follows:

	Land and buildings	
	2008	2007
	£	£
Expiry date:	31,000	-
2 to 5 years	-	31,000
Over 5 years	<u>31,000</u>	<u>31,000</u>
	<u>31,000</u>	<u>31,000</u>

The above lease expires in November 2013.

16. CONTROL

The Charity is controlled jointly by the trustees. There is no ultimate controlling party.

17. RELATED PARTIES TRANSACTIONS

Jeans for Genes

Since 1996 a Jeans for Genes (JGC) campaign has been held on an annual basis to raise money for research. Each year an agreement is drawn up between the parties involved, as shown below.

Both Jeans for Genes Limited (JGL) and JGC receive income from donations generated by the appeal. Any income received from JGL and JGC after deductions of all relevant costs, expenses, liabilities and other distributions, will result in the net proceeds being paid to each of the charities. (See note 12).

Chris Hughan (Chief Executive of PiA) and Rae McNairney (director of PiA) are both also directors of JGL and trustees of JGC. It is estimated that a total of £180,000 is receivable from the campaign for the current year (2007: £266,835). During the year, PiA loaned £200,000 (2007: £50,000) to JGC at an interest rate of 6% per annum. The loan was fully repaid in November 2008.

Participants of the Jeans for Genes Campaign are as follows:

The Chronic Granulomatous Disorder Research Trust ("CGDRT")
Seafields, Shootersway Lane, Berkhamsted, Herts HP4 3NP
(Charity no 1003425)
and

THE PRIMARY IMMUNODEFICIENCY ASSOCIATION

**NOTES TO THE FINANCIAL STATEMENTS (Continued)
FOR THE YEAR ENDED 31 DECEMBER 2008**

17. RELATED PARTIES TRANSACTIONS (Continued)

Jeans for Genes

The Society for Mucopolysaccharide Diseases ("MPS")
46 Woodside Road, Amersham, Bucks HP6 6AJ
(Charity no 287034)

and

The Primary Immunodeficiency Association ("PiA")
Alliance House, 12 Caxton Street, London SW1H 0QS
(Charity no 803217)

and

Great Ormond Street Hospital Children's Charity ("GOSHCC")
Great Ormond Street, London WC1N 3JH
(Charity no 235825)

(hereinafter jointly referred to as "the Charities")

(each of the above have nominated a person to be a member of JGC)

and

Jeans for Genes Campaign ("JGC")
40-41 Queen Square, London WC1N 3AJ (Charity no 1062206)

and

Jeans for Genes Ltd ("JGL") 40-41 Queen Square, London WC1N 3AJ
(Company no 03073588)

and

Great Ormond Street International Promotions Limited ("GOSIPL")
(Company no 2265303)